C.J.A. van Moorsel

1.3k total citations
16 papers, 1.1k citations indexed

About

C.J.A. van Moorsel is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C.J.A. van Moorsel has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C.J.A. van Moorsel's work include Cancer Treatment and Pharmacology (8 papers), Cancer therapeutics and mechanisms (6 papers) and Lung Cancer Treatments and Mutations (6 papers). C.J.A. van Moorsel is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Cancer therapeutics and mechanisms (6 papers) and Lung Cancer Treatments and Mutations (6 papers). C.J.A. van Moorsel collaborates with scholars based in Netherlands, Belgium and United States. C.J.A. van Moorsel's co-authors include Godefridus J. Peters, Herbert M. Pinedo, Andries M. Bergman, Judith R. Kroep, G. Veerman, Pieter E. Postmus, Jan B. Vermorken, C.L. van der Wilt, Stephen P. Ackland and W. J. F. van der Vijgh and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

C.J.A. van Moorsel

16 papers receiving 1.1k citations

Peers

Countries citing papers authored by C.J.A. van Moorsel

Since Specialization

Citations

This map shows the geographic impact of C.J.A. van Moorsel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.J.A. van Moorsel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.J.A. van Moorsel more than expected).

Fields of papers citing papers by C.J.A. van Moorsel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.J.A. van Moorsel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.J.A. van Moorsel. The network helps show where C.J.A. van Moorsel may publish in the future.

Co-authorship network of co-authors of C.J.A. van Moorsel

This figure shows the co-authorship network connecting the top 25 collaborators of C.J.A. van Moorsel. A scholar is included among the top collaborators of C.J.A. van Moorsel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.J.A. van Moorsel. C.J.A. van Moorsel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs 2000 ·European Journal of Cancer ·Andries M. Bergman, Giuseppe Giaccone, C.J.A. van Moorsel, R. Mauritz, Paul Noordhuis, Herbert M. Pinedo, Godefridus J. Peters	41
2	Basis for effective combination cancer chemotherapy with antimetabolites 2000 ·Pharmacology & Therapeutics ·Godefridus J. Peters, C.L. van der Wilt, C.J.A. van Moorsel, Judith R. Kroep, Andries M. Bergman, Stephen P. Ackland	246
3	Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours 2000 ·European Journal of Cancer ·C.J.A. van Moorsel, Herbert M. Pinedo, Kees Smid, (unknown), Daphne Voorn, G. Veerman, (unknown), W. J. F. van der Vijgh, Giuseppe Giaccone, Pieter E. Postmus, Godefridus J. Peters	28
4	Gemcitabine–cisplatin: A schedule finding study 1999 ·Annals of Oncology ·Judith R. Kroep, Godefridus J. Peters, C.J.A. van Moorsel, (unknown), J. B. Vermorken, H. M. Pinedo, C.J. van Groeningen	55
5	Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice 1999 ·European Journal of Cancer ·C.J.A. van Moorsel, Herbert M. Pinedo, G. Veerman, Jan B. Vermorken, Pieter E. Postmus, Godefridus J. Peters	64
6	Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors 1999 ·Annals of Oncology ·C.J.A. van Moorsel, Judith R. Kroep, Herbert M. Pinedo, G. Veerman, Daphne Voorn, Pieter E. Postmus, Jan B. Vermorken, C.J. van Groeningen, W. J. F. van der Vijgh, Godefridus J. Peters	76
7	Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines 1999 ·British Journal of Cancer ·C.J.A. van Moorsel, Herbert M. Pinedo, G. Veerman, Andries M. Bergman, C.M. Kuiper, Jan B. Vermorken, W. J. F. van der Vijgh, Godefridus J. Peters	176
8	Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung Cancer 1999 ·Journal of Clinical Oncology ·Judith R. Kroep, Giuseppe Giaccone, Daphne Voorn, Egbert F. Smit, Jos H. Beijnen, Hilde Rosing, C.J.A. van Moorsel, Cornelis J. van Groeningen, Pieter E. Postmus, Herbert M. Pinedo, Godefridus J. Peters	125
9	Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines 1999 ·Biochemical Pharmacology ·C.J.A. van Moorsel, Herbert M. Pinedo, Gijsbert Veerman, (unknown), Kees Smid, Willem J.P Loves, Jan B. Vermorken, Pieter E. Postmus, Godefridus J. Peters	34
10	Mechanisms of Synergism Between Gemcitabine and Cisplatin 1998 ·Advances in experimental medicine and biology ·C.J.A. van Moorsel, G. Veerman, J. B. Vermorken, Daphne Voorn, Judith R. Kroep, Andries M. Bergman, Herbert M. Pinedo, Godefridus J. Peters	15
11	Role of Deoxycytidine Kinase (dCK), Thymidine Kinase 2 (TK2), and Deoxycytidine Deaminase (dCDA) in the Antitumor Activity of Gemcitabine (dFdC) 1998 ·Advances in experimental medicine and biology ·Judith R. Kroep, C.J.A. van Moorsel, G. Veerman, Daphne Voorn, Richard M. Schultz, John F. Worzalla, Lee R. Tanzer, Ronald L. Merriman, Herbert M. Pinedo, Godefridus J. Peters	21
12	Differential Effects of Gemcitabine on Nucleotide Pools of 19 Solid Tumor Cell Lines 1998 ·Advances in experimental medicine and biology ·C.J.A. van Moorsel, G. Veerman, Veronique W.T. Ruiz van Haperen, Andries M. Bergman, Peter Buhl Jensen, Maxwell Sehested, Godefridus J. Peters	4
13	Combination chemotherapy studies with gemcitabine. 1997 ·PubMed ·C.J.A. van Moorsel, G. Veerman, Andries M. Bergman, (unknown), Jan B. Vermorken, Pieter E. Postmus, Godefridus J. Peters	81
14	Induction of in vivo resistance against gemcitabine (GEM, 2′,2′-difluorodeoxy-cytidine) 1997 ·Clinical Biochemistry ·Veronique W.T. Ruiz van Haperen, G. Veerman, C.J.A. van Moorsel, Godefridus J. Peters	1
15	Gemcitabine: Future Prospects of Single-Agent and Combination Studies 1997 ·The Oncologist ·C.J.A. van Moorsel, Godefridus J. Peters, Herbert M. Pinedo	76
16	Preclinical combination therapy with gemcitabine and mechanisms of resistance. 1996 ·PubMed ·Godefridus J. Peters, Veronique W.T. Ruiz van Haperen, Andries M. Bergman, G. Veerman, Evelien Smitskamp-Wilms, C.J.A. van Moorsel, Catharina M. Kuiper, Boudewijn J.M. Braakhuis	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact